Professor Andrea Laslop, MD, Austria

• Head of Scientific Office, Austrian Agency for Health and Food Safety, Austria
Clinical and non-clinical comparability for biologicals/biosimilars

Professor Andrea Laslop, MD
12 January 2015
Clinical and non-clinical comparability for biologicals/biosimilars

Andrea Laslop
Scientific Office, AGES, Vienna, Austria

European Medical Societies Roundtable on Biosimilars
12th January 2016, Brussels, Belgium
Disclaimer

• I attend this conference as an individual expert, and do not represent the CHMP or the Austrian Medicines Agency

• The views expressed here are my personal views, and may not be understood or quoted as being made on behalf of the CHMP or reflecting the position of the CHMP or the Austrian Medicines Agency
Overview

- **Non-clinical** comparability aspects
  - In vitro and in vivo studies

- **Clinical** comparability aspects
  - PK/PD studies
  - Efficacy and safety studies
  - Specific aspects on global development
  - Biosimilars of orphan products
Biosimilarity – general aspects

Development is a step-wise approach

1) Comparability at the **quality** level is key
2) Comparability at the **non-clinical** = functional level to give reassurance on similar effects
3) Comparability at the **clinical** level can and must be strengthened by a number of factors to be considered
   - Most homogeneous/sensitive **population**
   - Most sensitive **dose** (two doses?)
   - Most appropriate model and **statistical approach**
   - Most accurate definition of the **equivalence margin**
Non-clinical program

- **Step-wise and risk-based approach**
  - **Step 1** – In vitro studies:
    - always necessary, always first
    - most informative (functional assays for PD fingerprinting!)
  - **Step 2** – determine level of concern
  - **Step 3** – In vivo studies:
    - may become necessary, e.g. with novel excipients
Non-clinical comparability aspects

Non-clinical program

- **Important in vitro data:**
  - In general, comparative studies of in vitro function, e.g.
    - Comparative binding to target antigen(s)
    - Comparative binding to Fc receptors and complement
    - Fab-associated functions (neutralization, receptor activation or receptor blockade)
    - Fc-associated functions (ADCC and CDC, complement activation)

- **Animal data:** according the 3Rs → if at all, then
  - No studies in non-relevant species
  - or without a relevant model

No off-target tox studies!
Clinical comparability aspects

PK/PD studies

- **Step-wise** approach to clinical comparability
  - Start with PK ⇒ PD can be measured at the same time
- For PK in some instances **AUC** as primary endpoint (CI 80-125%) is sufficient (i.v. administration)
- Otherwise **Cmax** as co-primary endpoint
- Secondary PK endpoints
  - Tmax, Ctrough, clearance, etc.
Clinical comparability aspects

PK/PD studies

- May provide *pivotal equivalence data* in some cases
- **No further phase III trial** necessary
  - When *PD surrogate endpoints* are available
    - E.g. ANC for filgrastims, insulin clamp study for insulins, viral load for interferon $\alpha$, MRI for interferon $\beta$
- Biosimilar heparins rely on PD comparison only (no PK)
- Otherwise rather *unspecific PD parameters* as secondary endpoints provide supportive evidence
  - E.g. levels of various immunocompetent cells, CRP, ESR, etc.
Clinical comparability aspects

Efficacy/Safety studies

- **Pivotal clinical trials** are still needed in many instances (such as biosimilar antibodies)
- For **efficacy** – demonstration of **equivalence**
  - Especially for more complex molecules with several modes of action and where no good and single surrogate parameter exists
  - Also due to uncertainties in concluding on the absence (or presence) of clinical relevance of observed quality differences
  - However, the clinical trial is less sensitive than in vitro studies
  - Choice of the **clinical disease model**
    - Consider how to define a realistic equivalence margin
    - Population and concomitant therapy with lowest background noise
Clinical comparability aspects

Efficacy/Safety studies

- Overall the biosimilar should have the **same safety** profile as the innovator drug
  - Improved safety (e.g. lower immunogenicity) may be acceptable
- Part of the full safety database is necessary **pre-marketing**
  - Significant differences to be detected, e.g. in immunogenicity
  - Due to impurities, host cell proteins, other unknown factors?
  - Especially when **new expression systems or excipients** are used in the manufacturing process
Clinical comparability aspects

Safety database for biosimilars

- **Further safety data** to be delivered post-marketing
- **Traceability of products** is crucial
- Challenges in **collection of reliable information** on products and batches
  - Cooperation of clinicians most important
  - No agreed naming system yet
  - **WHO Biological Qualifyer (BQ) scheme**
    - Proposal for globally recognised unique identification code
    - 4 letter code as a complement to the INN
    - Currently not accepted by all regulators
Clinical comparability aspects

**Considerations on global development**

- Comparability at the clinical level is not expected to be significantly influenced by **ethnic factors** (are not different between treatment arms)
  - Acceptance of trials from other regions, other populations
  - As long as additional factors are respected in order to have a clinical model representative of the EU standard of care
  - E.g. adequate background treatment, adequate reference product, adequate GCP conditions of the study
Clinical comparability aspects

Considerations on global development

- **International dialogue of regulators**
  - International Pharmaceutical Regulators Forum (IPRF) – Working group on biosimilars (chair: Korea)
  - Representatives from Europe, North & Latin America, Asia, Africa + WHO
  - Inform, discuss and converge the legal, regulatory and scientific framework
  - **Biosimilar cluster**: t-cons between EMA (BMWP)-FDA-HC-PMDA
  - **Parallel scientific advice** between EMA and FDA

- **Harmonization** of regulatory requirements
  - Increase efficiency and consistency of regulatory decision taking
  - Facilitated by acceptance of **reference products** and **trial data** from different regions
Clinical comparability aspects

Biosimilars of orphan drugs

- **Feasibility challenges**
  - The number of patients will definitely preclude a statistical definition of “hard” equivalence margins
  - This will also preclude a reassuring **safety database** pre-licensing
  - **PD** surrogate endpoints often not available
  - Can **PK** comparison alone be sufficiently reassuring?
  - Additional challenges for **extrapolation** to other indications

- **Weight of evidence on the quality** (physicochemical and biological) **and** pre-clinical = **functional** in vitro comparison
Summary

Biosimilars are moving ahead

• **Challenges/changes** to be discussed
  - New approaches to comparison of **critical quality attributes**?
  - No more clinical **phase III efficacy and safety studies** required??
  - Where, when and to which extent to get the **safety/immunogenicity data** from?
  - How best to justify **extrapolation** to other indications?
  - How to reach **global convergence**?

• **Final goal** is to provide faster access of patients to affordable biological medicines at a sustainable price
Thank you for your attention